|
[Abstract] [PDF] [HTML] [Linked
References]
International Journal of Recent Trends in Science and Technology, ISSN 2277-2812 E-ISSN: 2249-8109
Volume 15, Issue 1, May 2015 pp 35-40
Research Article
A study of COX-2 expression in prostatic adenocarcinoma and its clinical relevance
Rukzana Fathima S1, Shalinee Rao2, Simon Durai Raj C3, Sunil Shroff4, D Prathiba5, Sandhya Sundaram6
{1P. G. Student, 3Research Scholar, 5, 6Professor, Department of Pathology} {4Professor, Department of Urology}
Sri Ramachandra Medical College and Research Institute Porur, Chennai-600116. Tamil Nadu, INDIA.
2Additional Professor, Department of Pathology, AIIMS, Rishikesh, Uttarakhand, INDIA.
Abstract
Objective: The purpose of the present study was to determine the expression of cyclooxygenase-2 (COX-2) in patients with carcinoma of prostate and its clinical significance in relation to clinical pathological parameters. Materials and Methods: A total of 100 cases of prostatic tissue specimens consisting of 88 adenocarcinoma prostate and 12 Benign Prostatic Hyperplasia (BPH) were included in the study. Formalin-fixed paraffin-embedded tissue samples were initially stained using Hematoxylin and Eosin stains and graded according to Gleason scoring system. Immunohistochemistry for COX-2 were performed on these blocks. The expression pattern was determined and correlated with clinicopathological parameters. Results: A majority of well differentiated prostate carcinoma and BPH cases showed strong COX-2 expression. In contrast poorly differentiated and most of the moderately differentiated cases showed weak positivity. COX-2 expression pattern for different grades were found to be statistically significant (p=0.03). Clinically proven metastatic samples showed negative COX-2 expression. Correlation between serum PSA level with COX-2 expression did not show any significant relationship. Conclusion: COX-2 expression was found to be strong in well differentiated carcinoma of prostate irrespective of the PSA levels. Inhibitors of COX-2 may prove useful as a alternative therapeutic adjunct for the treatment of low grade prostatic carcinoma.
|
